Efficacy and safety of antiretrovirals in HIV-infected patients with cancer

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages O672-O679

  Torres, H A ^a   Rallapalli, V ^a   Saxena, A ^a   Granwehr, B P ^a   Viola, G M ^a   Ariza Heredia, E ^a   Adachi, J A ^a   Chemaly, R F ^a   Marfatia, R ^a   Jiang, Y ^a   Mahale, P ^a   Kyvernitakis, A ^a   Fanale, M A ^a   Mulanovich, V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

HIV; AIDS; Antiretroviral; Cancer; Raltegravir

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MIRTAZAPINE; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEOPLASM; NEPHROLITHIASIS; NEUROPATHY; OSTEOPENIA; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; UNPLEASANT DREAM; ADVERSE EFFECTS; CAUCASIAN; COMPLICATION; ETHNOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TEXAS; YOUNG ADULT;

EID: 84913607363     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12589     Document Type: Article

References (24)

1. DHHS. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in hiv-1-infected adults and adolescents. 2013: Department of health and human services. (last accessed 11 July 2013)
2. Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-aids-defining cancers in people with hiv infection. J Clin Oncol 2009; 27: 884-890.
3. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-aids-defining cancers in patients with hiv on haart therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445-454.
4. Deeken JF, Tjen ALA, Rudek MA et al. The rising challenge of non-aids-defining cancers in hiv-infected patients. Clin Infect Dis 2012; 55: 1228-1235.
5. Bonnet F, Burty C, Lewden C et al. Changes in cancer mortality among hiv-infected patients: the mortalite 2005 survey. Clin Infect Dis 2009; 48: 633-639.
6. Monforte A, Abrams D, Pradier C et al. Hiv-induced immunodeficiency and mortality from aids-defining and non-aids-defining malignancies. AIDS 2008; 22: 2143-2153.
7. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have hiv/aids. Lancet Oncol 2011; 12: 905-912.
8. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 2009; 72: 10-20.
9. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in aids-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-1491.
10. Fulco PP, Hynicka L, Rackley D. Raltegravir-based haart regimen in a patient with large b-cell lymphoma. Ann Pharmacother 2010; 44: 377-382.
11. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in hiv-infected adults and adolescents: recommendations from cdc, the national institutes of health, and the hiv medicine association of the infectious diseases society of america. MMWR Recomm Rep 2009; 58: 1-207; quiz CE201-204.
12. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for hiv infection among adults, adolescents, and children aged <18 months and for hiv infection and aids among children aged 18 months to <13 years-united states, 2008. MMWR Recomm Rep 2008; 57: 1-12.
13. Persad GC, Little RF, Grady C. Including persons with hiv infection in cancer clinical trials. J Clin Oncol 2008; 26: 1027-1032.
14. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44: 111-145.
15. Berretta M, Di Benedetto F, Dal Maso L et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in hiv-positive patients. Anticancer Drugs 2013; 24: 212-218.
16. Johnson M. Raltegravir use in special populations. Eur J Med Res 2009; 14(suppl 3): 43-46.
17. Deeken JF, Mitsuyasu RT, Little RF. Treating hiv+ patients for non-aids-defining cancers (nadcs) in the era of targeted chemotherapy: an aids malignancy consortium study of sunitinib in patients on art. J Clin Oncol 2010; 28 (suppl. 15s): Abstract TPS161.
18. Bower M, McCall-Peat N, Ryan N et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104: 2943-2946.
19. Song IH, Borland J, Chen S, Savina P, Peppercorn AF, Piscitelli S. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013; 57: 4394-4397.
20. Levine AM, Noy A, Lee JY et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in aids-related lymphoma: aids malignancy consortium study 047. J Clin Oncol 2013; 31: 58-64.
21. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in hiv-associated non-hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol 2012; 87: 330-333.
22. Pakkala S, Chen Z, Rimland D et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118: 164-172.
23. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with aids-associated kaposi sarcoma. Am J Clin Oncol 2004; 27: 81-84.
24. Cianfrocca M, Lee S, Von Roenn J et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated kaposi's sarcoma: an eastern cooperative oncology group (ecog) and aids malignancy consortium (amc) trial. Cancer Chemother Pharmacol 2011; 68: 827-833.